What's new? Log in Free sign up

OrganiGram (OGI)

Company Profile

Company profile

Ticker

OGI

Exchange

Website

www.organigram.ca

CEO

Ms. Beena G. Goldenberg

Incorporated

Canada (Federal)

Location

New Brunswick, Canada

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

[object Object]

SEC CIK

Corporate docs

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

OGI stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Annual report (Canada) (amended)

Material Change Report

Organigram Acquires Motif, Becoming Canada’s Largest Cannabis Company by Market Share

Organigram Launches FAST™ Nanoemulsion Gummies

Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment

Organigram Announces Appointment of Craig Harris to Board of Directors

Current report (foreign)

Notice of Change of Auditor

Second “Jupiter” investment strengthens Organigram’s European access, including to the high-growth market of Germany

Organigram Signs Three Year Supply Agreement with Avida Medical in UK

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

BT DE Investments Inc.

BT DE Investments Inc.

BT DE Investments Inc.

BT DE Investments Inc.

BT DE Investments Inc.

ETF MANAGERS GROUP, LLC

ETF MANAGERS GROUP, LLC

BT DE Investments Inc.

ETF MANAGERS GROUP, LLC

ETF MANAGERS GROUP, LLC

Financial summary

Financial statements Chart OGI financial data

Quarter (USD)	Sep 23	Aug 22	Aug 21	Aug 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Sep 23	Aug 22	Aug 21	Aug 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from OrganiGram earnings reports.

Institutional ownership, Q3 2024

OGI institutional ownership history Ownership history

49.1% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	73	80	-8.8%
Opened positions	7	11	-36.4%
Closed positions	14	17	-17.6%
Increased positions	19	20	-5.0%
Reduced positions	19	14	+35.7%

13F shares	Current	Prev Q	Change
Total value	12.85 bn	8.49 bn	+51.3%
Total shares	39.85 mm	21.03 mm	+89.5%
Total puts	43.70 k	70.60 k	-38.1%
Total calls	220.90 k	273.30 k	-19.2%
Total put/call ratio	0.2	0.3	-23.4%

Largest owners	Shares	Value	Change
BT DE Investments	32.57 mm	$58.96 mm	+113.6%
Toroso Investments	1.95 mm	$3.53 bn	+8.3%
Millennium Management	1.27 mm	$2.31 bn	NEW
Renaissance Technologies	893.45 k	$1.62 bn	+9.4%
AdvisorShares Investments	741.78 k	$1.34 bn	-25.8%
BMO Bank of Montreal	458.69 k	$810.49 mm	-0.6%
Two Sigma Investments	319.48 k	$578.27 mm	+171.6%
Dimensional Fund Advisors	316.02 k	$571.99 mm	+23.1%
Baader Bank	252.81 k	$455.57 mm	-0.0%
Penserra Capital Management	164.54 k	$297.00 k	-6.7%

Largest transactions	Shares	Bought/sold	Change
BT DE Investments	32.57 mm	+17.32 mm	+113.6%
Millennium Management	1.27 mm	+1.27 mm	NEW
AdvisorShares Investments	741.78 k	-258.34 k	-25.8%
Two Sigma Investments	319.48 k	+201.87 k	+171.6%
Toroso Investments	1.95 mm	+149.17 k	+8.3%
Renaissance Technologies	893.45 k	+76.50 k	+9.4%
Polar Asset Management Partners	0.00	-75.00 k	EXIT
Dimensional Fund Advisors	316.02 k	+59.36 k	+23.1%
MS Morgan Stanley	71.24 k	+46.57 k	+188.7%
Graham Capital Management	45.43 k	+45.43 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

Cannabis Player Organigram Clocks Q4 Gross Margin Of 37% On Higher Efficiency Across Cultivation And Higher Recreational Sales, Stock Soars

Organigram's Q4 sales hit $31.22 million, boosted by recreational and international growth, with adjusted gross margin improving to 37% of net revenue.

OrganiGram Holdings Earnings Review: Q4 Summary

OrganiGram Holdings Q4 Earnings Assessment

OrganiGram Holdings Q4 FY24 Sales C$44.70M Beat C$42.98M Estimate, Net Loss Of C$5.4M Vs. C$26.59M YoY

Earnings Scheduled For December 18, 2024

Press releases

From Benzinga Pro

Organigram Reports Fourth Quarter and Fiscal 2024 Results

Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2

Organigram to Report Fourth Quarter and Fiscal 2024 Results on December 18, 2024

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results

Organigram Acquires Motif, Becoming Canada's Largest Cannabis Company by Market Share

Transformational Acquisition Results in Cannabis Pure Play Leader, Coast-to-Coast Geographic Strength and Proven Excellence in Consumer-Focused Innovation, Cultivation, Product Development, Extraction and

Organigram Launches FAST™ Nanoemulsion Gummies

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.